Market open
Enlivex Therapeutics/$ENLV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enlivex Therapeutics
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Ticker
$ENLV
Sector
Trading on
Industry
Biotechnology
Headquarters
Ness Ziona, Israel
Employees
-
ISIN
IL0011319527
Website
ENLV Metrics
BasicAdvanced
$24M
-
-$0.73
0.85
-
Price and volume
Market cap
$24M
Beta
0.85
52-week high
$1.29
52-week low
$0.84
Average daily volume
61K
Financial strength
Current ratio
6.842
Quick ratio
6.557
Long term debt to equity
1.268
Total debt to equity
2.264
Management effectiveness
Return on assets (TTM)
-30.10%
Return on equity (TTM)
-55.95%
Valuation
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-1.612
Growth
Earnings per share change (TTM)
-53.23%
3-year earnings per share growth (CAGR)
-3.33%
ENLV News
AllArticlesVideos
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress
GlobeNewsWire·3 weeks ago
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
GlobeNewsWire·3 weeks ago
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Enlivex Therapeutics stock?
Enlivex Therapeutics (ENLV) has a market cap of $24M as of May 15, 2025.
What is the P/E ratio for Enlivex Therapeutics stock?
The price to earnings (P/E) ratio for Enlivex Therapeutics (ENLV) stock is 0 as of May 15, 2025.
Does Enlivex Therapeutics stock pay dividends?
No, Enlivex Therapeutics (ENLV) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Enlivex Therapeutics dividend payment date?
Enlivex Therapeutics (ENLV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enlivex Therapeutics?
Enlivex Therapeutics (ENLV) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.